TABLE 1.

Patient characteristics and treatment

Treatment	Patient no.	Sexa/age (yr)	Karnofsky score	Duration of TB (yr)	Extent of disease	Drug resistanceb	Drug treatmentb
Daily rhuIL-2	1	M/47	100	6	Moderate	H, R, S, E, Th, Et, C	H, Z, Et, T, C, O
	2	M/34	90	15	Severe	H, R, S, E, C	H, S, Z, K, Th, Et
	3	M/41	90	2	Moderate	H, R	H, S, E, Z, Th, Et, O
	4	M/41	90	1	Moderate	H, R, S, E, O	H, Z, K, Th, Et, C
	5	M/55	80	1	Moderate	H, R	E, Z, Et, T, O
	6	F/30	90	1	Moderate	H, R, S, C, Rb	H, E, K, Th, Et, T
	7	F/30	90	1	Moderate	H, R, S	H, E, Z, Th, Et
	8	F/34	100	5	Moderate	H, R	H, R, E, K, Th, T
	9	F/21	70	5	Severe	H, R, S, Th	H, R, S, E, Z, Et
	10	F/19	60	2	Severe	H, R, S, Th	H, R, S, E, Z, Et
Placebo	11	F/31	90	3	Severe	H, R, S, E, K, Th, C	H, E, Z, Th, Et, C, O
	12	F/38	90	1	Severe	H, R, E, K, Rb	H, R, Z, Th, Et, C, O
	13	F/19	60	2	Moderate	H, R	H, R, E, Z, Th, Et, T
	14	F/24	90	10	Moderate	H, R	H, E, Z, Th, T

^aM, male; F, female. 

^bH, isoniazid; R, rifampin; S, streptomycin; E, ethambutol; Z, pyrazinamide; K, kanamycin; Th, thiacetazone; Et, ethionamide; T, terizidone; C, clofazimine; O, ofloxacin; Rb, rifabutin.